FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- The 5 Shifts That Could Remake Lyophilization By 2040
- Your 7 Decisions To Make Before MES Configuration
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- You Can't CAPA What You Can't Classify
GUEST COLUMNISTS
-
When Lyophilization Fails At Scale, First Scrutinize Your Formulation
When lyophilizing a challenging biologic drug product, use an integrated approach optimizing formulation and process parameters together.
-
The 5 Shifts That Could Remake Lyophilization By 2040
Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
-
Your 7 Decisions To Make Before MES Configuration
Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
BIOSIMILAR WHITE PAPERS
-
A Comprehensive Solution For Adventitious Agent Testing
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
Why Biopharma Breakthroughs Aren't Moving The Market10/20/2025
Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer3/24/2025
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
Innovation In Filtration3/18/2025
Filtration removes contaminants to ensure safety and is essential in various applications, from lab-scale tasks to GMP production. Explore how its simplicity and reliability make it indispensable.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing5/12/2025
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- BioSim Proposes Incorporating Measures Into Electoral Programs To Promote Biosimilar Medicines
- Bio-Thera Announces NMPA Approval Of BAT2306, The First Secukinumab Biosimilar Approved In China
- Samsung Bioepis Releases Fourth Quarter 2026 Biosimilar Market Report Highlighting Importance Of Supply Continuity
- Celltrion Healthcare Canada Ltd. Announces The Opening Of A New Office In Montreal, Strengthening Its Growing Presence In Quebec
- Formycon And Biocelys Combine Complementary Development And Manufacturing Expertise In New Biosimilar Project FYB286
- Samsung Bioepis Enters Into Landmark 10-Year Agreement To Supply Eculizumab To The Brazilian Market, Anchoring Long-Term Growth In Latin America
- Alvotech Receives FDA Approval For New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch
NEWSLETTER ARCHIVE
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
- 10.22.26 -- FDA Modernizes Container Closure Guidance: What Is Changing
- 10.21.26 -- A Sustainable Future: Leveraging 3Rs To Innovate And Accelerate In Testing
- 10.20.26 -- Reduce risk. Move Annex 1 forward.
